---
document_datetime: 2023-09-21 17:17:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/efavirenzemtricitabinetenofovir-disoproxil-krka-epar-all-authorised-presentations_en.pdf
document_name: efavirenzemtricitabinetenofovir-disoproxil-krka-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7626352
conversion_datetime: 2025-12-22 21:55:14.655753
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name                                    | Strength                 | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size           |
|------------------|----------------------------------------------------|--------------------------|-----------------------|---------------------------|-----------------------|---------------------|
| EU/1/17/1263/001 | Efavirenz/Emtricitabine/ Tenofovir disoproxil Krka | 600 mg / 200 mg / 245 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 30 tablets          |
| EU/1/17/1263/002 | Efavirenz/Emtricitabine/ Tenofovir disoproxil Krka | 600 mg / 200 mg / 245 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 90 (3 x 30) tablets |